Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): A multicentre, open-label, randomised phase 2 trial

The Lancet Oncology

Volumn 17, Issue 3, 2016, Pages 378-388

  Armstrong, Andrew J ^a   Halabi, Susan ^a   Eisen, Tim ^b   Broderick, Samuel ^c   Stadler, Walter M ^d   Jones, Robert J ^e   Garcia, Jorge A ^f   Vaishampayan, Ulka N ^g   Picus, Joel ^h   Hawkins, Robert E ⁱ   Hainsworth, John D ^j   Kollmannsberger, Christian K ^k   Logan, Theodore F ^l   Puzanov, Igor ^m   Pickering, Lisa M ⁿ   Ryan, Christopher W ^o   Protheroe, Andrew ^p   Lusk, Christine M ^q   Oberg, Sadie ^q   George, Daniel J ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f LERNER RESEARCH INSTITUTE   (United States)

^g WAYNE STATE UNIVERSITY   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k BRITISH COLUMBIA CANCER AGENCY   (Canada)

^l INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁿ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^o OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q SYNEOS HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; EVEROLIMUS; LIVER ENZYME; SUNITINIB; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CANCER PROGNOSIS; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG SAFETY; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; FLATULENCE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HAND FOOT SYNDROME; HEADACHE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFECTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; KIDNEY CARCINOMA; LETHARGY; LEUKOCYTE COUNT; LIMB PAIN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; METASTATIC NON CLEAR CELL RENAL CELL CARCINOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL CHEST PAIN; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; CANCER STAGING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; CARCINOMA, RENAL CELL; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PYRROLES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84960494358     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00515-X     Document Type: Article

References (27)

1. Bitting RL, Madden J, Armstrong AJ Therapy for non-clear cell histologies in renal cancer. Curr Clin Pharmacol 2011, 6:169-180.
2. Shuch B, Amin A, Armstrong AJ, et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol 2015, 67:85-97.
3. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26:127-131.
4. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. Proc Am Soc Clin Oncol 2007, 25(suppl 18). abstr 5010.
5. Lee JL, Ahn JH, Lim HY, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012, 23:2108-2114.
6. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Proc Am Soc Clin Oncol 2007, 25(suppl 18). abstr 5033.
7. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
8. Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013, 24:1026-1031.
9. Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014, 32:2765-2772.
10. Chaux A, Albadine R, Schultz L, et al. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. Hum Pathol 2013, 44:2323-2330.
11. Davis CF, Ricketts CJ, Wang M, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014, 26:319-330.
12. Armstrong AJ, George DJ, Halabi S Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 2012, 30:3402-3407.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
14. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
15. Cella D, Yount S, Du H, et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 2006, 4:191-199.
16. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007, 13:671s-679s.
17. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
18. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
19. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
20. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
21. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
22. Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 2015, published online Nov 25. 10.1016/j.eururo.2015.10.049.
23. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22:909-918.
24. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013, 31:181-186.
25. Choueiri TK, Fay AP, Gray KP, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014, 25:2178-2184.
26. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014, 46:225-233.
27. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.